Thursday Night's Show Highlights:
The most exciting stock Jim's seen in a long time, and it's ready to rocket even higher!
Thursday, December 18, 2014
Providing show recaps for Wednesday, Thurs., Friday, including verbatim Game Plans and Lightning Round stock picks...
Jim: Here on Mad Money, we're always searching for the next big biotech stock, the next drug company that's going to give you massive multi-year gains, thanks to some sort of game-changing innovation. The gold standard on Mad Money is Regeneron, the $42 billion company with a $423 stock, and a stable of blockbuster, and potential blockbuster drugs.
Yep, when I started recommending it on this show, a little more than nine years ago, it was a tiny speculative $5 stock with big dreams, but nothing in the way of products, let alone profits. Since then, Regeneron's given you one of the greatest runs in biotech history. It's up 8,375%, and I think it's not done.
But at this point, what gets us really excited are the stocks that could be the next Regeneron, which is why tonight I am doing something I typically do not do. I am circling back to the amazing ISIS Pharmaceuticals.
Last week, we spoke to the CEO of ISIS shortly after the company made a groundbreaking presentation at the big annual American Society of Hematology meeting, or ASH. And I think the market's not giving this company nearly enough credit here, in part because the stock is down $2 bucks since that interview. That is creating an incredible entry point, people... buy, buy, buy... for ISIS. But out of everything in the pipeline, tonight I want to talk to you about a single drug that I think is not getting enough attention. I think it's an absolute game changer. It's a drug that could potentially send the stock soaring much higher from these levels, all by itself. I'm referring to FXI, the anti-coagulent that ISIS highlighted at the American Society of Hematology meeting earlier this month. I think FXI is nothing short of revolutionary. This drug is what's known as an anti-thrombotic, meaning it prevents blood clots. There are a lot of these on the market right now, but they all have really serious issues. Here's the problem. While we have a number of drugs that can prevent blood clots, they tend to have some pretty unfortunate side effects, particularly risk of bleeding or bleed out. But this is a serious problem, because people need to take these anti-coagulants when they go in for surgery. Your surgeon doesn't want a potentially lethal blood clot getting into your veins. However, your surgeon also doesn't want you to bleed to death. So doctors need to walk a very fine line whenever they use the current crop of anti-coagulants...